SEC Filings

Form Description Filing date View
8-K

Report of unscheduled material events or corporate event

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
8-K

Report of unscheduled material events or corporate event

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
3

Initial filing by director officer or owner of more than ten percent.

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML
4

Statement of changes in beneficial ownership of securities

View HTML

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline